COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We perform...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/59 |